Friday, October 30, 2009
Thursday, October 29, 2009
Might be worth it to load up on Lifeline Biotech (LLBO), my man
A risk but you never know. LLBO is only 0.0026, From FavStocks.com :
"...More details after contacting Jim Holmes, CEO of Lifeline Biotech, to provide even further clarification of todays news. Jim Holmes has been in contact with their FDA consulting firm who advised the FDA is 30-60 days past the normal time expected to provide a response. The FDA will determine if their technology and testing of over 600 patients would meet the requirements for a 510(k). Jim went further to say that he expects a response on this by the “end of November” but its not guaranteed and its all in the FDA’s hands now. Jim has done everything he possibly can at this point including calling the FDA to get status but the “FDA will not say one word”. LINK
"...More details after contacting Jim Holmes, CEO of Lifeline Biotech, to provide even further clarification of todays news. Jim Holmes has been in contact with their FDA consulting firm who advised the FDA is 30-60 days past the normal time expected to provide a response. The FDA will determine if their technology and testing of over 600 patients would meet the requirements for a 510(k). Jim went further to say that he expects a response on this by the “end of November” but its not guaranteed and its all in the FDA’s hands now. Jim has done everything he possibly can at this point including calling the FDA to get status but the “FDA will not say one word”. LINK
AVAX Currently Pending Clinical Trials News for its Pipeline (OTC:AVXT.PK)
Long item from StocksHaven on October 14th but worth reading if you're in AVXT or thinking about it. Here's the last paragraph:
Overall Sentiment
Overall Sentiment
Having finally managed to find the means for capital in order to fund ongoing research and development costs, all the while establishing stability by joining the OTC market, the company seems to have moved past its most troubled times and onto greener pastures. The end of 2009, and beginning of 2010 should provide a rebirth for AVAX, boosting investor confidence as they begin to focus on the phase II and phase III clinical trials respectively. The results of these trials remains unknown, however, when taking a look at other struggling cancer biotechs which are entering or have entered phase III, it is easy to depict which way this stock and its market cap of 27.10M will go — just take a look at Cell Therapeutics (NASDAQ:CTIC).
Bad news today from Genta, my man
Interim analysis of Phase III data on Genta’s melanoma treatment, Genasense®, revealed that it did not meet one of its primary endpoints or any of the secondary endpoints that are evaluable at this time. The company has thus decided to postpone submission of an NDA this year.
Genta, already trading below $1, lost just over 81% of its value in early morning trading. After closing yesterday at $0.65, it opened today at $0.12....LINK
Wednesday, October 28, 2009
Genta conference call Thursday October 29, 2009 at 8:00 AM ET, my man
Genta Incorporated (OTCBB: GETA - News) announced that the Company will host a conference call and live audio webcast to review top-line results of its Phase 3 trial of Genasense® in patients with advanced melanoma. The call will take place on Thursday October 29, 2009 at 8:00 AM ET.
Participants can access the live call by dialing (877) 634-8606 (U.S. and Canada) or (973) 200-3973 (International). The access code for the live call is Genta Incorporated. The call will also be webcast live at http://www.genta.com/investorrelation/events.html.
Good luck to all GETA shareholders! GETA is currently at 0.65 Link to today's press release
Participants can access the live call by dialing (877) 634-8606 (U.S. and Canada) or (973) 200-3973 (International). The access code for the live call is Genta Incorporated. The call will also be webcast live at http://www.genta.com/investorrelation/events.html.
Good luck to all GETA shareholders! GETA is currently at 0.65 Link to today's press release
Take a look at Mammoth Energy Group (MMTE), my man
A Toucan stock pick...Currently at 0.0005 Here's a link to their site
Why You Can't Get the Swine Flu Vaccine
From today's Wall Street Journal:
Why You Can't Get the Swine Flu Vaccine
U.S. regulations are too cautious. Europe has adopted a more sensible approach.
By SCOTT GOTTLIEB
Why You Can't Get the Swine Flu Vaccine
U.S. regulations are too cautious. Europe has adopted a more sensible approach.
By SCOTT GOTTLIEB
Though the swine flu is widespread in 46 states many Americans are still waiting to get their vaccines. The Obama administration blames the shortage on manufacturing delays at the five firms making these products. But production issues only explain part of the shortfall. Also to blame are a series of policy decisions that reflect our extreme caution when it comes to these products.
Though the swine flu is widespread in 46 states many Americans are still waiting to get their vaccines. The Obama administration blames the shortage on manufacturing delays at the five firms making these products. But production issues only explain part of the shortfall. Also to blame are a series of policy decisions that reflect our extreme caution when it comes to these products.
From a regulatory standpoint, vaccines are unique in many ways. Since we distribute them widely to otherwise healthy people, they deserve careful oversight. But right now we are shunning new, superior vaccine science by being overly cautious.
The first fateful policy decision, made last spring, was to forgo vaccine additives—called adjuvants—that activate the immune system and make shots more potent. Adjuvants allow a smaller supply of vaccine stock to be stretched across more doses. These adjuvants are included in H1N1 vaccines world-wide, but not in the U.S.
Why do adjuvants matter? An adjuvanted H1N1 vaccine being used in Europe contains 3.75 micrograms of vaccine stock. The same vaccine in the U.S., without the adjuvant, requires 15 micrograms of vaccine for equal potency. If we used adjuvants, we could have had four times the number of shots with the same raw material....
How can we improve our regulatory process to prevent such shortages? First, the Food and Drug Administration (FDA) needs to create a review pathway for adjuvants that can become components of multiple vaccines. One, called monophosphoryl lipid A, was recently the first modern adjuvant to be approved in the U.S.—in this case as part of a vaccine for cervical cancer. We've been slow to integrate vaccine additives, bowing to imprudent activism and litigation. The European strategy of having adjuvants preapproved, as part of mock up pandemic vaccines, was smart. We should adopt it.
Second, the FDA requires vaccines to sit for weeks after they come off the manufacturing line to make sure they haven't grown bacterial impurities. This is why most of the H1N1 vaccine supply is released in waves and won't be ready until later this winter. The FDA can work with manufacturers to develop better standardized tools, called assays, to quickly assess new vaccine....
Monday, October 26, 2009
HTDS to acquire a stem cell company, my man?
Interesting, check out this Pink Sheet Filing from yesterday: LINK
And this from their October 12, 2009 press release:
"....This is experimental data that Slavica Biochem group obtained on laboratory animals. Preliminary experiments will begin within a project aimed at promoting stem cell graft survival in the model of traumatic brain injury in rats. The company invites its followers to review all the Pink Sheets filings..."
And this from their October 12, 2009 press release:
"....This is experimental data that Slavica Biochem group obtained on laboratory animals. Preliminary experiments will begin within a project aimed at promoting stem cell graft survival in the model of traumatic brain injury in rats. The company invites its followers to review all the Pink Sheets filings..."
Keep an eye on BizAuctions (BZCN), my man
This may move up soon. Currently at 0.0013
Check out what SmallCap Networks has to say:
"Finally, BizAuctions Inc. - despite an erratic past - may be working on a breakout move that actually develops some follow-through.
This is nothing more than a notification that things are different now for BizAuctions shares... we have buying volume. We saw a ton of it Friday, and today's isn't bad either. We also saw a couple of heavy accumulation days two weeks ago. It's not a game-changer for BZCN (yet), but clearly something is going on that's different.
As for how I'd handle it, I'd do nothing yet. I'm going to out BizAuctions Inc. on my watchlist, so subscribers to the newsletter may be seeing this name again... either in the community pages or in the e-mail newsletter - I'm not sure. I just get the feeling BZCN could be worth monitoring for a while."
And StockHaven:
"As the holiday season fast approaches during one of the most hard hit economic times in recent memory, certain discount companies look to profit and gain recognition, differentiating themselves from the pack. One of these such companies is BizAuctions Inc. (OTC:BZCN.OB), which is quickly gaining momentum in a $60B excess inventory liquidation market. The concept is simple, they offer eBay liquidation services for companies who have excess inventory, returns, and overstock items. Given that eBay is one of those companies which is recession proof, investors should feel a little more confident should they choose to place their eggs in this basket. At first glance, this may seem like a simple concept, however it made them a hefty revenue of $1,340,904 during six months ended June/30/2009, and that’s not too bad for a high growth company worth an estimated $640M in market cap. Despite the struggling economy, BizAuctions has continued to decrease operating and net losses, all the while maintaining a revived sense of optimism after eBay (NASDAQ:EBAY) hit their highest level in 10-months and exceeded Wall Street’s forecast. BizAuctions alsoruns a retail clothing store named “Lucky 7’s” which opened at the Chula Vista Center, on May/29/09 next to Macy’s in Chula Vista, CA. It is also important to remember that during the last holiday season in December of 2008, the company’s shares reached a one year high of 0.11 price per share."
Check out what SmallCap Networks has to say:
"Finally, BizAuctions Inc. - despite an erratic past - may be working on a breakout move that actually develops some follow-through.
This is nothing more than a notification that things are different now for BizAuctions shares... we have buying volume. We saw a ton of it Friday, and today's isn't bad either. We also saw a couple of heavy accumulation days two weeks ago. It's not a game-changer for BZCN (yet), but clearly something is going on that's different.
As for how I'd handle it, I'd do nothing yet. I'm going to out BizAuctions Inc. on my watchlist, so subscribers to the newsletter may be seeing this name again... either in the community pages or in the e-mail newsletter - I'm not sure. I just get the feeling BZCN could be worth monitoring for a while."
And StockHaven:
"As the holiday season fast approaches during one of the most hard hit economic times in recent memory, certain discount companies look to profit and gain recognition, differentiating themselves from the pack. One of these such companies is BizAuctions Inc. (OTC:BZCN.OB), which is quickly gaining momentum in a $60B excess inventory liquidation market. The concept is simple, they offer eBay liquidation services for companies who have excess inventory, returns, and overstock items. Given that eBay is one of those companies which is recession proof, investors should feel a little more confident should they choose to place their eggs in this basket. At first glance, this may seem like a simple concept, however it made them a hefty revenue of $1,340,904 during six months ended June/30/2009, and that’s not too bad for a high growth company worth an estimated $640M in market cap. Despite the struggling economy, BizAuctions has continued to decrease operating and net losses, all the while maintaining a revived sense of optimism after eBay (NASDAQ:EBAY) hit their highest level in 10-months and exceeded Wall Street’s forecast. BizAuctions alsoruns a retail clothing store named “Lucky 7’s” which opened at the Chula Vista Center, on May/29/09 next to Macy’s in Chula Vista, CA. It is also important to remember that during the last holiday season in December of 2008, the company’s shares reached a one year high of 0.11 price per share."
Sunday, October 25, 2009
FDA OKs Use of BioCryst Flu Drug, my man
BIRMINGHAM, Ala. (The Street) The Food and Drug Administration has authorized the emergency use of peramivir, an experimental antiviral drug, to treat swine flu, also known as H1N1 influenza. The drug is being developed by BioCryst (BCRX Quote) LINK
If only they would do this for Ampligen and Hemispherx Biopharma.
If only they would do this for Ampligen and Hemispherx Biopharma.
Don't forget about ChinaBioToday, my man
Good source of information about the Chinese biotech industry, Click Here
Lots of talk about Biovest International (BVTI.PK), my man
Some people on the Yahoo and Google message boards are saying BVTI is going to be $30, $50, $100 PPS soon....I don't know about that, I'm not invested in this stock. Biovest has had money issues. November 2nd may be a key date. I'm trying to find info about this. In the meantime, see for yourself:
Yahoo Google
BVTI is currently at 0.44. Here's a link to their site.
Yahoo Google
BVTI is currently at 0.44. Here's a link to their site.
Saturday, October 24, 2009
A little more about Wellstar International (WLSI), my man
I mentioned the other day that I "loaded up" on Wellstar International (WLSI) and I want to stress that I did this because the stock is cheap, not because I believe anything is going to happen, good or bad, with WLSI in the near future. Investing in stocks is kind of like gambling but you have the time to do your research. Spending $35 to get 300,000 shares is not a huge risk. It's money I'm willing to spend on the chance that WLSI will someday be 0.0075 or even just 0.0025. It's just a chance to make extra money someday.
Friday, October 23, 2009
Can we have a Friday touchdown, my man?
Come on HEB, IMGG, BIEL, HTDS, NEPH....somebody take off like a rocket todayThursday, October 22, 2009
I have loaded up on Wellstar International (WLSI), my man
Hard To Treat Diseases at 0.0100, my man
Obviously HTDS stock owners aren’t too happy about the current price at 0.0100. I’m not. A while back I predicated that HTDS would be somewhere between 0.05 and 0.10 by October and I thought maybe I was being conservative. But I think most HTDS shareholders including myself are still confident that HTDS is going to pay off big-time at some point. HTDS continues to issue positive press releases but solid information such as the Q3 financials may give HTDS the boost it needs. I don’t doubt for a moment that we’ll see HTDS back at 0.02 and beyond in the not so distant future.
You think HEB sucks? I understand, my man
What a frustrating stock to own and we may not hear from the FDA about Ampligen until sometime in 2010. It's not all Hemispherx BioPharma's fault. The FDA should have issued another definitive date for approval or an official update of sort kind after saying back in May that they needed another "one to two weeks". After five months of waiting we still don't know what hell is going on.
No big CTIC bump today, my man
Odd considering the positive news from yesterday. I thought it would close today over $1.20 today at least but CTIC is worth hanging on to, my man.
Keep an eye on Cell Therapeutics on Thursday, my man
Some very good news from CTIC released a little while ago:
Pixantrone Produces High Rates of Complete Remission in Multiple Relapsed and Refractory Indolent and Aggressive Non-Hodgkin's Lymphoma
Pixantrone Produces High Rates of Complete Remission in Multiple Relapsed and Refractory Indolent and Aggressive Non-Hodgkin's Lymphoma Overview of Phase II-III Clinical Trials will be Presented at International Lymphoma Meeting
SEATTLE, Oct. 22 / Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an overview of CTI's pixantrone phase II and phase III clinical studies that demonstrated high rates of complete remission (CR) in relapsed/refractory aggressive and indolent non-Hodgkin's lymphoma (NHL) patients.....LINK
Pixantrone Produces High Rates of Complete Remission in Multiple Relapsed and Refractory Indolent and Aggressive Non-Hodgkin's Lymphoma
Pixantrone Produces High Rates of Complete Remission in Multiple Relapsed and Refractory Indolent and Aggressive Non-Hodgkin's Lymphoma Overview of Phase II-III Clinical Trials will be Presented at International Lymphoma Meeting
SEATTLE, Oct. 22 / Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an overview of CTI's pixantrone phase II and phase III clinical studies that demonstrated high rates of complete remission (CR) in relapsed/refractory aggressive and indolent non-Hodgkin's lymphoma (NHL) patients.....LINK
Wednesday, October 21, 2009
Ampligen is still in limbo, my man
October 16, 2009, Washington Business Journal:
A decision on Hemispherx BioPharma’s new drug application for Ampligen, twice delayed by the FDA earlier this year, is still in limbo.
William A. Carter, CEO of the Center City biotech company, said last week the company is responding to issues raised by the Food and Drug Administration during its review of Ampligen, an experimental treatment for chronic fatigue syndrome.
Hemispherx has spent more than $500 million and more than three decades developing the drug.
Carter last week provided an update on the status of the FDA’s review of Ampligen to BioMedReports, a Web site that provides information on life sciences firms.
“We continue to be in contact with the [FDA] concerning certain requests they have made over the last year that have to do with toxicology,” Carter said. “This is nonclinical work on the drug. We have continued to complete reports and we expect to sometime this quarter, the fourth quarter, complete a set of requirements [from the FDA] that have to do with preclinical toxicology.”
In its latest quarterly report filed with the Securities and Exchange Commission, Hemispherx noted it is working with the Lovelace Respiratory Research Institute in Albuquerque, N.M., on animal toxic studies in support of its Ampligen application.
The August filing noted the studies were requested by the FDA and that the studies were “substantially completed,” with summary reports issued to the agency during the third quarter.
“Data for final FDA reports are presently undergoing internal auditing at Lovelace and Hemispherx with a projected completion of the final report for late 2009 to early 2010,” the company stated in the filing....
Click here for the whole article.
Speculative stock: China SXAN Biotech, Inc. (Public, OTC:CSXB), my man
I just came across this company a little while ago. Don't know anything about it and I'll take a look at tomorrow:
China SXAN Biotech, Inc. (Public, OTC:CSXB): China SXAN Biotech, Inc., formerly Advance Technologies, Inc., is a development-stage company. On July 10, 2007, the Company acquired the outstanding capital stock of American SXAN Biotech, Inc. (American SXAN). American SXAN is a holding company that on October 31, 2006, acquired 100% of the stock of Tieli Xiaoxinganling Forest Breeding Co., Ltd. (Tieli Xiaoxinganling). Tieli Xiaoxinganling is engaged in the business of manufacturing and marketing wines and tonics derived from domesticated forest frogs.
China SXAN Biotech, Inc. (Public, OTC:CSXB): China SXAN Biotech, Inc., formerly Advance Technologies, Inc., is a development-stage company. On July 10, 2007, the Company acquired the outstanding capital stock of American SXAN Biotech, Inc. (American SXAN). American SXAN is a holding company that on October 31, 2006, acquired 100% of the stock of Tieli Xiaoxinganling Forest Breeding Co., Ltd. (Tieli Xiaoxinganling). Tieli Xiaoxinganling is engaged in the business of manufacturing and marketing wines and tonics derived from domesticated forest frogs.
Monday, October 19, 2009
Keep an eye on AVAX Technologies (AVXT), my man
This is another long-term stock I like. I meant to include this in my October 13th post about long-term stocks. Currently at 0.21
Saturday, October 17, 2009
Friday, October 16, 2009
Thursday, October 15, 2009
Wednesday, October 14, 2009
Tuesday, October 13, 2009
Some of my favorite long-term stocks,my man
Long-term can have a vague meaning to some as different people will likely have different ideas as to what "long-term" is. For me, when I say long-term, it generally means I'm willing to hold a stock and wait anywhere from 3 months to a year or more. I'm not expecting any big gains in the near future with these stocks but I'm confident that at least some of them will pay off at some point:
Advanced Cell Technology, Inc. (ACTC)
Angiotech Pharmaceuticals, Inc. (ANPI)
Capital Trust (CT)...when the economy recovers this should return to $30
China Precision Steel, Inc. (CPSL)...China is a growing country and you build things with steel
Cell Therapeutics, Inc (CTIC)
Ecotality, Inc. (ETLY)...Electric cars are in our future
Genta Incorporated (GETA)
Hana Biosciences, Inc. (HNAB)
Imaging Diagnostic Systems, Inc. (IMDS)
MultiCell Technologies, Inc (MCET)
Neopharm Inc. (NEOL)
Oilsands Quest Inc. (BQI)...lots of potential oil
Peregrine Pharmaceuticals, Inc. (PPHM)
Palatin Technologies, Inc. (PTN)
RegeneRx Biopharmaceuticals, Inc (RGN)
Solos Endoscopy, Inc. (SNDY)
Viral Genetics, Inc (VRAL)
Advanced Cell Technology, Inc. (ACTC)
Angiotech Pharmaceuticals, Inc. (ANPI)
Capital Trust (CT)...when the economy recovers this should return to $30
China Precision Steel, Inc. (CPSL)...China is a growing country and you build things with steel
Cell Therapeutics, Inc (CTIC)
Ecotality, Inc. (ETLY)...Electric cars are in our future
Genta Incorporated (GETA)
Hana Biosciences, Inc. (HNAB)
Imaging Diagnostic Systems, Inc. (IMDS)
MultiCell Technologies, Inc (MCET)
Neopharm Inc. (NEOL)
Oilsands Quest Inc. (BQI)...lots of potential oil
Peregrine Pharmaceuticals, Inc. (PPHM)
Palatin Technologies, Inc. (PTN)
RegeneRx Biopharmaceuticals, Inc (RGN)
Solos Endoscopy, Inc. (SNDY)
Viral Genetics, Inc (VRAL)
Monday, October 12, 2009
Sunday, October 11, 2009
MultiCell Technologies, Inc. is 'One to Watch', my man
This article on the International Business Times site appeared in August but I believe MultiCell Technologies is a good long-term stock to consider. Take a look, MCET is still pretty cheap at 0.02 :
MultiCell Technologies, Inc. (MCET.OB) is 'One to Watch'
Headquartered in Woonsocket, Rhode Island, MultiCell Technologies, Inc. is an integrated biopharmaceutical company. Trading on the OTCBB, their commitment is to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technologies. The company plans to pursue strategic alliances to better penetrate the various markets for their therapeutics.
The company’s drug development program focuses on the modulation of the immune system. Their lead drug candidates include drugs to treat multiple sclerosis (MS)-related chronic fatigue, relapsing-remitting MS, type-1 diabetes, and infectious disease. MultiCell Technologies, Inc.’s therapeutic pipeline includes MCT-125, which is directed at treating chronic fatigue in MS patients. MCT-125 completed a 138 patient Phase II clinical trial and demonstrated strong efficacy in reducing fatigue in MS patients....Click here to read the rest.
MultiCell Technologies, Inc. (MCET.OB) is 'One to Watch'
Headquartered in Woonsocket, Rhode Island, MultiCell Technologies, Inc. is an integrated biopharmaceutical company. Trading on the OTCBB, their commitment is to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technologies. The company plans to pursue strategic alliances to better penetrate the various markets for their therapeutics.
The company’s drug development program focuses on the modulation of the immune system. Their lead drug candidates include drugs to treat multiple sclerosis (MS)-related chronic fatigue, relapsing-remitting MS, type-1 diabetes, and infectious disease. MultiCell Technologies, Inc.’s therapeutic pipeline includes MCT-125, which is directed at treating chronic fatigue in MS patients. MCT-125 completed a 138 patient Phase II clinical trial and demonstrated strong efficacy in reducing fatigue in MS patients....Click here to read the rest.
Saturday, October 10, 2009
Industry leaders express concern as FDA clamps down on 510(k)s
From the Massachusetts Medical Devices Journal:
An internal Food & Drug Administration memo leaked by the Wall Street Journal indicating that the Food & Drug Administration plans to tighten up its 510(k) approval process for medical devices has industry leaders expressing concern.
According to the memo, written by FDA device evaluation office head Donna-Bea Tillman, the agency is already clamping down on the 510(k) process, by which the majority of medical devices are approved.
"It's Autumn, and change is in the air. This is particularly true for our 510k program," Tillman wrote, according to the Journal, adding that in order to "get a better lay of the land" branch chiefs are now required to pass along applications for devices with a new "indication" or use "that you have never cleared for that device type."
That's a deviation from former FDA protocol, two FDA scientists told the newspaper. But new protocol is "just the first of what I am sure will be many things that we will be doing to strengthen the 510k and all of our other programs in the months ahead," Tillman wrote.
Thomas Sommer, president of MassMEDIC, the Massachusetts medical device industry council, told MassDevice that the 510(k) procedure, which is used for devices that are "substantially equivalent" to products already on the market, is one of the world's most stringent approval processes.
"Our concern as an industry is that this change in protocol will bring us back to the days in the mid-1990s when 510(k)s took well over a year for FDA to clear," Sommer told us. "This industry is one of the most heavily regulated industries. It complies with FDA guidelines and regulations on everything from developing products to manufacturing to marketing and sales. Companies do a very good job of complying with a vast web of regulations.
"Our companies already comply with the toughest product review protocol in the world. It's viewed as the gold standard and most companies are delighted to go though the process, because it means they have achieved the highest certification of safety and effectiveness in the world."
A Johnson & Johnson spokeswoman sounded a similar note in speaking with the Journal, saying that adding evidentiary requirements to the 510(k) process "would raise development costs substantially while also creating barriers to market entry that would reduce competition."
Friday, October 9, 2009
ZZZZZZZZ....Hemispherx BioPharma, my man
The slumber continues...Interview with Dr. William Carter, CEO of Hemispherx Biopharma
"An interview with Dr. William Carter, CEO of Hemispherx Biopharma (AMEX:HEB) regarding the status of the NDA for Ampligen as a first line treatment for Chronic Fatigue Syndrome as well as his company's pipeline plans for Alferon LDO (Low Dose Oral) application." - That's nice but all I want to know now is if Ampligen is going to be approved or not by the FDA. WTF is going on?
"An interview with Dr. William Carter, CEO of Hemispherx Biopharma (AMEX:HEB) regarding the status of the NDA for Ampligen as a first line treatment for Chronic Fatigue Syndrome as well as his company's pipeline plans for Alferon LDO (Low Dose Oral) application." - That's nice but all I want to know now is if Ampligen is going to be approved or not by the FDA. WTF is going on?
Thursday, October 8, 2009
Wednesday, October 7, 2009
Nice day for Hard to Treat Diseases (HTDS), my man
Finished at 0.0150 and the company issued the following release today:
Hard to Treat Diseases (HTDS) Obtains GMP Certificate from Russian FDA
Hard to Treat Diseases (HTDS) Obtains GMP Certificate from Russian FDA
Update on NeoPharm (NEOL), my man
On September 10th I mentioned NeoPharm as a good long-term bio-tech stock to get into. After a voluntary delisting from Nasdaq earlier this year NEOL has climbed from 0.07 in February to it's current price at 0.39 on the OTC BB.
Neopharm has 5 drug product candidates in various stages of clinical and pre-clinical development for the treatment of cancer, interstitial pulmonary fibrosis and asthma. The company has cash on hand to fund anticipated development activities into the second quarter of 2010.
Below is a link from an article on NeoPharm from OneMedPlace.
NeoPharm: A Pipeline with Multiple Catalysts
I don't know what the future holds for NEOL but if you invest in enough companies like this your patience should be rewarded. Buy low, sell high and be patient, my man.
Neopharm has 5 drug product candidates in various stages of clinical and pre-clinical development for the treatment of cancer, interstitial pulmonary fibrosis and asthma. The company has cash on hand to fund anticipated development activities into the second quarter of 2010.
Below is a link from an article on NeoPharm from OneMedPlace.
NeoPharm: A Pipeline with Multiple Catalysts
I don't know what the future holds for NEOL but if you invest in enough companies like this your patience should be rewarded. Buy low, sell high and be patient, my man.
Tuesday, October 6, 2009
Peregrine Pharmaceuticals, Inc. (PPHM), my man
MYMAN got into Peregrine Pharmaceuticals (PPHM) last year. There's been no big payoff yet but I'm stickin' with PPHM. They reported positive news this week on their drug bavituximab (see below) But the company may do a reverse split within a month to remain trading on Nasdaq.Currently trading at 0.68
October 5, 2009: Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
Advanced Cell Technology now on the OTCBB, my man
WORCESTER, Mass.--Advanced Cell Technology, Inc. (Advanced Cell, ACT) (OTCBB: ACTC - News) announced today that effective immediately the Company's shares will be traded on the Over-the-Counter Bulletin Board under its previous ticker symbol ACTC. The Company is now fully reporting and up-to-date with all of its filing requirements. The Company’s stock had previously traded on the Pink Sheets. LINK
Good long-term stock, my man. Currently trading at 0.13
Good long-term stock, my man. Currently trading at 0.13
Transdel Pharmaceuticals announces positive Phase 3 study results for Lead Topical Pain Drug Ketotransdel(R), my man
But the stock doesn't really go anywhere. Currently at $2.12.
Monday, October 5, 2009
Transdel Pharmaceuticals: Phase 3 clinical study results to be announced October 6, my man
Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) today announced that it will host a conference call and audio webcast on Tuesday, October 6, 2009 at 9:00 am, eastern, to announce the top-line results of its Phase 3 clinical study for Ketotransdel®, a topical cream based non-steroidal anti-inflammatory drug ("NSAID") for acute pain. A press release will be issued on Tuesday, October 6, 2009 at 7:30 am, eastern.
The CEO of Angiotech Pharmaceuticals (ANPI) brought 49,500 shares of ANPI, my man
President and CEO of Angiotech Pharmaceuticals Inc. (ANPI) William L Hunter buys 49,500 shares of ANPI on 09/29/2009 at an average price of $1.9 a share.
Angiotech Pharmaceuticals Inc. is a Canadian pharmaceutical company dedicated to the development of medical device coatings and treatments for chronic inflammatory diseases through reformulation of the anticancer drug paclitaxel. These treatments are based upon the company's discovery that paclitaxel blocks an important cellular pathway involved in inflammation. The company's goal is to establish a leadership position in the development of treatments for chronic inflammatory diseases. Angiotech Pharmaceuticals Inc. has a market cap of $146.6 million; its shares were traded at around $1.76 with and P/S ratio of 0.5.
LINK
Angiotech Pharmaceuticals Inc. is a Canadian pharmaceutical company dedicated to the development of medical device coatings and treatments for chronic inflammatory diseases through reformulation of the anticancer drug paclitaxel. These treatments are based upon the company's discovery that paclitaxel blocks an important cellular pathway involved in inflammation. The company's goal is to establish a leadership position in the development of treatments for chronic inflammatory diseases. Angiotech Pharmaceuticals Inc. has a market cap of $146.6 million; its shares were traded at around $1.76 with and P/S ratio of 0.5.
LINK
Sunday, October 4, 2009
Take a look at AVAX Technologies, (OTC:AVXT), my man
AVAX Technologies, Inc. (AVAX) is a development stage biotechnology company specializing in the development and future commercialization of individualized vaccine therapies and other technologies for the treatment of cancer. The Company's vaccine consists of autologous (the patient’s own) cancer cells that have been treated with a chemical (haptenized) to make them more visible to the patient’s immune system. AVAX refer to its cancer vaccine technology as autologous cell vaccine immunotherapy and to the vaccine as the AC Vaccine. Its clinical trials for the AC Vaccine have concentrated on melanoma, ovarian carcinoma, which are its primary indications, and non-small cell lung cancer. The Company refers to its AC Vaccine candidates as: M-Vax, L-Vax and O-Vax. M-Vax is for the treatment of melanoma. L-Vax is for the treatment of non-small cell lung cancer. O-Vax is for the treatment of ovarian cancer.
Currently trading at 0.0770.
Related article: Melanoma Drug Called a “Breakthrough” After Study
ScienceDaily: Umbilical Cord Blood As A Readily Available Source For Off-the-shelf, Patient-specific Stem Cells
Can you say, Cord Blood America Inc. (CBAI.OB), my man?
Umbilical Cord Blood As A Readily Available Source For Off-the-shelf, Patient-specific Stem Cells
ScienceDaily (Oct. 2, 2009) — Human umbilical cord blood cells may be far more versatile than previous research has indicated. Scientists report that they have successfully reprogrammed human umbilical cord blood cells into cells with properties similar to human embryonic stem cells. The results are significant as they identify cord blood as a convenient source for generating cells with a theoretically limitless potential.
Umbilical cord blood cells can successfully be reprogrammed to function like embryonic stem cells, setting the basis for the creation of a comprehensive bank of tissue-matched, cord blood-derived induced pluripotent stem (iPS) cells for off-the-shelf applications, report researchers at the Salk Institute for Biological Studies and the Center for Regenerative Medicine in Barcelona, Spain. "Cord blood stem cells could serve as a safe, "ready-to-use" source for the generation of iPS cells, since they are easily accessible, immunologically immature and quick to return to an embryonic stem cell-like state," says Juan-Carlos Izpisúa Belmonte, Ph.D., a professor in the Salk's Gene Expression Laboratory, who led the study published in the October issue of the journal Cell Stem Cell.
Link to rest of this article.
Umbilical Cord Blood As A Readily Available Source For Off-the-shelf, Patient-specific Stem Cells
ScienceDaily (Oct. 2, 2009) — Human umbilical cord blood cells may be far more versatile than previous research has indicated. Scientists report that they have successfully reprogrammed human umbilical cord blood cells into cells with properties similar to human embryonic stem cells. The results are significant as they identify cord blood as a convenient source for generating cells with a theoretically limitless potential.
Umbilical cord blood cells can successfully be reprogrammed to function like embryonic stem cells, setting the basis for the creation of a comprehensive bank of tissue-matched, cord blood-derived induced pluripotent stem (iPS) cells for off-the-shelf applications, report researchers at the Salk Institute for Biological Studies and the Center for Regenerative Medicine in Barcelona, Spain. "Cord blood stem cells could serve as a safe, "ready-to-use" source for the generation of iPS cells, since they are easily accessible, immunologically immature and quick to return to an embryonic stem cell-like state," says Juan-Carlos Izpisúa Belmonte, Ph.D., a professor in the Salk's Gene Expression Laboratory, who led the study published in the October issue of the journal Cell Stem Cell.
Link to rest of this article.
Saturday, October 3, 2009
Take a look at Advaxis, Inc. (OTCBB: ADXS), my man
Advaxis, Inc., formerly Great Expectations, Inc., is a development-stage biotechnology company focused on developing cancer vaccines that utilize mechanisms of immunity. The Company uses the Listeria system licensed from the University of Pennsylvania (Penn) to secrete a protein sequence containing a tumor-specific antigen. The Company has focused its initial development efforts upon cancer vaccines targeting cervical, head and neck, breast, prostate, and other cancers. Its products in development include Lovaxin C and Lovaxin B, Lovaxin P
Currently trading at 0.126
October 1, 2009 press release: Updated Advaxis Phase I Survival Data Indicates Long-Term Immune Protection
Currently trading at 0.126
October 1, 2009 press release: Updated Advaxis Phase I Survival Data Indicates Long-Term Immune Protection
Cell Therapeutics poll results, my man
Are you stayin' with Cell Therapeutics (CTIC), my man?
Hell yes, wait for Pixantrone approval: 67
No, I'm out: 37
Unsure: 14
Hell yes, wait for Pixantrone approval: 67
No, I'm out: 37
Unsure: 14
Subscribe to:
Posts (Atom)
